The US FDA has extended its approval for AstraZeneca’s acalabrutinib to include initial treatment of mantle cell lymphoma (MCL) in adults who cannot undergo a hematopoietic stem cell transplant. MCL is a rare, aggressive blood cancer and acalabrutinib, sold as Calquence, is the first of its kind approved as front-line therapy for the disease. The drug already had accelerated approval for adults whose MCL had failed at least one prior treatment.
Mandiant warns of attacks on newly-disclosed Ivanti remote takeover threat
Google’s Mandiant team has issued an alert about a remote code execution flaw in the Ivanti Connect Secure VPN platform. The vulnerability, designated CVE-2025-22457, is
